

1 **Adaptation of Host Transmission Cycle During *Clostridium difficile***

2 **Speciation**

3 Nitin Kumar^{1,*§}, Hilary P. Browne^{1,*}, Elisa Viciani¹, Samuel C. Forster^{1,2,3}, Simon Clare⁴,
4 Katherine Harcourt⁴, Mark D. Stares¹, Gordon Dougan⁴, Derek J. Fairley⁵, Paul Roberts⁶,
5 Munir Pirmohamed⁶, Martha RJ Clokie⁷, Mie Birgitte Frid Jensen⁸, Katherine R.
6 Hargreaves⁷, Margaret Ip⁹, Lothar H. Wieler^{10,11}, Christian Seyboldt¹², Torbjörn Norén^{13,14},
7 Thomas V. Riley^{15,16}, Ed J. Kuijper¹⁷, Brendan W. Wren¹⁸, Trevor D. Lawley^{1,§}

8

9 ¹Host-Microbiota Interactions Laboratory, Wellcome Sanger Institute, Hinxton, CB10 1SA, UK.

10 ²Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria,
11 3168, Australia.

12 ³Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria, 3800, Australia.

13 ⁴Wellcome Sanger Institute, Hinxton, CB10 1SA, UK.

14 ⁵Belfast Health and Social Care Trust, Belfast, Northern Ireland.

15 ⁶University of Liverpool, Liverpool, UK.

16 ⁷Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, LE1 7RH, UK.

17 ⁸Department of Clinical Microbiology, Slagelse Hospital, Ingemannsvej 18, 4200, Slagelse, Denmark.

18 ⁹Department of Microbiology, Chinese University of Hong Kong, Shatin, Hong Kong.

19 ¹⁰Institute of Microbiology and Epizootics, Department of Veterinary Medicine, Freie Universität Berlin, Berlin,
20 Germany.

21 ¹¹Robert Koch Institute, Berlin, Germany.

22 ¹²Institute of Bacterial Infections and Zoonoses, Federal Research Institute for Animal Health (Friedrich-
23 Loeffler-Institut), Jena, Germany.

24 ¹³Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

25 ¹⁴Department of Laboratory Medicine, Örebro University Hospital Örebro, Sweden

26 ¹⁵Department of Microbiology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Western
27 Australia, Australia.

28 ¹⁶School of Pathology & Laboratory Medicine, The University of Western Australia, Western Australia,
29 Australia

30 ¹⁷Section Experimental Bacteriology, Department of Medical Microbiology, Leiden University Medical Center,
31 Leiden, Netherlands.

32 ¹⁸Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, University of
33 London, London, UK.

34

35 *These authors contributed equally to this work

36

37 §Corresponding authors

38 Trevor D. Lawley: Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK, CB10 1SA, Phone

39 01223 495 391, Fax 01223 495 239, Email: tl2@sanger.ac.uk

40 Nitin Kumar: Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK, CB10 1SA, Phone 01223

41 495 391, Fax 01223 495 239, Email: nk6@sanger.ac.uk

42

43 Bacterial speciation is a fundamental evolutionary process characterized by diverging
44 genotypic and phenotypic properties. However, the selective forces impacting genetic
45 adaptations and how they relate to the biological changes underpinning the formation of a
46 new bacterial species remain poorly understood. Here we show that the spore-forming,
47 healthcare-associated enteropathogen *Clostridium difficile* is actively undergoing speciation.
48 Applying large-scale genomic analysis of 906 strains, we demonstrate that the ongoing
49 speciation process is linked to positive selection on core genes in the newly forming species
50 that are involved in sporulation and the metabolism of simple dietary sugars. Functional
51 validation demonstrates the new *C. difficile* produce more resistant spores and show
52 increased sporulation and host colonization capacity when glucose or fructose is available for
53 metabolism. Thus, we report the formation of an emerging *C. difficile* species, selected for
54 metabolizing simple dietary sugars and producing high levels of resistant spores that is
55 adapted for healthcare-mediated transmission.

56

57

58

59

60

61

62

63

64

65

66

67 The formation of a new bacterial species from its ancestor is characterized by genetic
68 diversification and biological adaptation¹⁻⁴. For decades, a polyphasic examination⁵, relying
69 on genotypic and phenotypic properties of a bacterium, has been used to define and
70 discriminate a “species”. The bacterial taxonomic classification framework has more recently
71 used large-scale genome analysis to incorporate aspects of a bacterium’s natural history, such
72 as ecology⁶, horizontal gene transfer¹, recombination² and phylogeny³. Although a more
73 accurate definition of a bacterial species can be achieved with whole-genome-based
74 approaches, we still lack a fundamental understanding of how selective forces impact
75 adaptation of biological pathways and phenotypic changes leading to bacterial speciation. In
76 this work, we describe the genome evolution and biological changes during the ongoing
77 formation of a new *C. difficile* species that is highly specialized for human transmission in the
78 modern healthcare system.

79 *C. difficile* is a strictly anaerobic, Gram-positive bacterial species that produces highly
80 resistant, metabolically dormant spores capable of rapid transmission between mammalian
81 hosts through environmental reservoirs⁷. Over the past four decades, *C. difficile* has emerged
82 as the leading cause of antibiotic-associated diarrhea worldwide, with a large burden on the
83 healthcare system^{7,8}. To define the evolutionary history and genetic changes underpinning the
84 emergence of *C. difficile* as a healthcare pathogen, we performed whole-genome sequence
85 analysis of 906 strains isolated from humans (n = 761), animals (n = 116) and environmental
86 sources (n = 29) with representatives from 33 countries and the largest proportion originating
87 from the UK (n = 465) (Supplementary Fig. 1; Supplementary Table 1; Supplementary Table
88 2). This dataset is summarized visually here <https://microreact.org/project/H1QidSp14>. Our
89 collection was designed to capture comprehensive *C. difficile* genetic diversity⁹ and includes
90 13 high-quality and well-annotated reference genomes (Supplementary Table 2). Robust
91 maximum likelihood phylogeny based on 1,322 concatenated single-copy core genes (Fig.

92 1a; Supplementary Table 3) illustrates the existence of four major phylogenetic groups within
93 this collection. Bayesian analysis of population structure (BAPS) using concatenated
94 alignment of 1,322 single-copy core genes corroborated the presence of the four distinct
95 phylogenetic groupings (PGs 1-4) (Fig. 1a) that each harbor strains from different
96 geographical locations, hosts and environmental sources which indicates signals of sympatric
97 speciation. Each phylogenetic group also harbors distinct clinically relevant ribotypes (RT):
98 PG1 (RT001, 002, 014); PG2 (RT027 and 244); PG3 (RT023 and 017); PG4 (RT078, 045
99 and 033).

100 The phylogeny was rooted using closely related species (*C. bartlettii*, *C. hiranonis*, *C.*
101 *ghonii* and *C. sordellii*) as outgroups (Fig. 1a). This analysis indicated that three phylogenetic
102 groups (PG1, 2 and 3) of *C. difficile* descended from the most diverse phylogenetic group
103 (PG4). This was also supported by the frequency of single-nucleotide polymorphism (SNP)
104 differences in pairwise comparisons between strains of PG4 and each of the other PGs versus
105 the level of pairwise SNP differences between comparisons of PGs 1, 2 and 3 to each other
106 (Supplementary Fig. 2). Interestingly, bacteria from PG4 display distinct colony
107 morphologies compared to bacteria from PG 1, 2 and 3 when grown on nutrient agar plates
108 (Supplementary Fig. 3), suggesting a link between *C. difficile* colony phenotype and
109 genotype that distinguishes PG 1, 2 and 3 from PG4.

110 Our previous genomic study using 30 *C. difficile* genomes indicated an ancient,
111 genetically diverse species that likely emerged 1 to 85 million years ago¹⁰. Testing this
112 estimate using our larger dataset indicated the species emerged approximately 13.5 million
113 years (12.7-14.3 million) ago. Using the same BEAST¹¹ analysis on our substantially
114 expanded collection, we estimate the most recent common ancestor (MRCA) of PG4 (using
115 RT078 lineage) arose approximately 385,000 (297,137-582,886) years ago. In contrast, the
116 MRCA of the PG1, 2 and 3 groups (using RT027 lineage) arose approximately 76,000

117 (40,220-214,555) years ago. Bayesian skyline analysis reveals a population expansion of
118 PG1, 2 and 3 groups (using RT027 lineage) around 1595 A.D., which occurred shortly before
119 the emergence of the modern healthcare system in the 18th century (Supplementary Fig. 4).
120 Combined, these observations suggest that PG4 emerged prior to the other PGs and that the
121 PG1, 2 and 3 population structure started to expand just prior to the implementation of the
122 modern healthcare system¹². We therefore refer to PG1, 2 and 3 groups as *C. difficile* “clade
123 A” and PG4 as *C. difficile* “clade B”.

124 To investigate genomic relatedness, we next performed pairwise Average Nucleotide
125 Identity (ANI) analysis (Fig. 1b). This analysis revealed high nucleotide identity (ANI >
126 95%) between PGs 1, 2 and 3 indicating that bacteria from these groups belong to the same
127 species; however, ANI between PG4 and any other PG was either less than the species
128 threshold (ANI > 95%) or on the borderline of the species threshold (94.04%-96.25%) (Fig.
129 1b). To detect recombination events, FastGEAR analysis¹³ was performed on whole-genome
130 sequences of 906 strains. While analysis identified increased recombination within *C. difficile*
131 clade A (PG1-PG2: 1-102, PG1-PG3: 1-214, PG2-PG3: 1-96) (Supplementary Fig. 5) a
132 restricted number of recombination events between *C. difficile* clade A and clade B was
133 observed (PG1-PG4: 1-20, PG2-PG4: 1-25, PG3-PG4: 1-46). This analysis strongly indicates
134 the presence of recombination barriers in the core genome that further distinguishes the two
135 *C. difficile* clades and could encourage sympatric speciation. Furthermore, accessory genome
136 functional analysis also shows a clear separation between clade A and clade B
137 (Supplementary Fig. 6; Supplementary Table 4-5). We also observe a higher number of
138 pseudogenes in clade A compared to clade B (Supplementary Fig. 7; Supplementary Table 6-
139 11). Taken together, these results indicate different selection pressures on the genomes of *C.*
140 *difficile* clades A and B.

141 In addition to reduced rates of recombination events, advantageous genetic variants in
142 a population driven by positive selective pressures, termed positive selection, are also a
143 marker of speciation⁶. We determined the Ka/Ks ratios and identified 172 core genes in clade
144 A and 93 core genes in clade B that were positively selected (Ka/Ks >1) (Fig. 2a;
145 Supplementary Table 12-13). Functional annotation and enrichment analysis identified
146 positively selected genes involved in carbohydrate and amino acid metabolism, sugar
147 phosphotransferase system (PTS) and spore coat architecture and spore assembly in clade A
148 (Fig. 2b). In contrast, the sulphur relay system was the only enriched functional category in
149 positively selected genes from clade B. Notably, 26% (45 in total) of the positively selected
150 genes in *C. difficile* clade A produce proteins that are either directly involved in spore
151 production, are present in the mature spore proteome¹⁴ or are regulated by Spo0A¹⁵ or its
152 sporulation-specific sigma factors¹⁶ (Fig. 2c). In contrast, no positively selected genes are
153 directly involved in spore production in *C. difficile* clade B; however, 22.5% (21 genes in
154 total) are either present in the mature spore proteome or are regulated by Spo0A or its
155 sporulation specific sigma factors (Supplementary Fig. 8). The lack of overlap between
156 sporulation-associated positively selected genes in the two lineages suggests a divergence of
157 spore-mediated transmission functions. In addition, these results suggest functions important
158 for host-to-host transmission have evolved in *C. difficile* clade A.

159 We found 20 positively selected genes (Supplementary Table 12) in clade A whose
160 products are components of the mature spore^{14,15} and could contribute to environmental
161 survival¹⁷. As an example, *sodA* (superoxide dismutase A), a gene associated with spore coat
162 assembly, has three-point mutations which are present in all clade A genomes but absent in
163 clade B genomes (Supplementary Fig. 9). Spores derived from diverse *C. difficile* clades have
164 a wide variation in resistance to microbiocidal free radicals from gas plasma¹⁸. To investigate
165 if the phenotypic resistance properties of spores from the new lineage have evolved, we

166 exposed spores from both clades to hydrogen peroxide, a commonly used healthcare
167 environmental disinfectant¹⁷. Spores derived from clade A were more resistant to 3% ($P =$
168 0.0317) and 10% hydrogen peroxide ($P = 0.0317$) when compared to spores from clade B,
169 although there was no difference in survival at 30% peroxide likely due to the overpowering
170 bactericidal effect at this concentration ($P = 0.1667$) (Fig. 3a).

171 The master regulator of *C. difficile* sporulation, *Spo0A*, is under positive selection in
172 *C. difficile* clade A only. *Spo0A* also controls other host colonization factors, such as flagella,
173 and carbohydrate metabolism, potentially serving to mediate cellular processes to direct
174 energy to spore production and host colonization to facilitate host-to-host transmission¹⁵.
175 Interestingly, the clade A genomes contain genes under positive selection that are involved in
176 fructose metabolism (*fruABC* and *fruK*), glycolysis (*pgk* and *pyk*), sorbitol (CD630_24170)
177 and ribulose metabolism (*repI*), and conversion of pyruvate to lactate (*ldh*). To further
178 explore the link between sporulation and carbohydrate metabolism in clade A, we analyzed
179 positively selected genes using KEGG pathways¹⁹ and manual curation. Manual curation of
180 key enriched pathways across the 172 positively selected core genes in *C. difficile* clade A
181 identified a complete fructose-specific PTS pathway and identified four genes (30%, 4/13)
182 involved in anaerobic glycolysis during glucose metabolism (Supplementary Fig. 10). Other
183 genes associated with enriched PTS pathways include genes used for the cellular uptake and
184 metabolism of mannitol, cellobiose, glucitol/sorbitol, galactitol, mannose and ascorbate.
185 Furthermore, comparative analysis of carbohydrate active enzymes (CAZymes)²⁰ identified a
186 clear separation of CAZymes between *C. difficile* clade A and clade B (Supplementary Fig.
187 11; Supplementary Table 14). Combined, these observations suggest a divergence of
188 functions between two *C. difficile* clades linked to metabolism of a broad range of simple
189 dietary sugars²¹.

190 The simple sugars glucose and fructose are increasingly used in diets within Western
191 societies²¹. Interestingly, trehalose, a disaccharide of glucose, used as a food additive has
192 impacted the emergence of some human virulent *C. difficile* variants²². Based on our genomic
193 analysis, we hypothesized that dietary glucose or fructose could differentially impact host
194 colonization by spores from *C. difficile* clade A or clade B. We therefore supplemented the
195 drinking water of mice with either glucose, fructose or ribose and challenged with clade A or
196 clade B strains. Ribose metabolic genes were not under positive selection so this sugar was
197 included as a control. Mice challenged with clade A spores exhibited increased bacterial load
198 when exposed to dietary glucose ($P = 0.048$) or fructose ($P = 0.0045$) compared to clade B
199 (Fig. 3b). No difference in bacterial load was observed between *C. difficile* clade A and clade
200 B without supplemented sugars or when supplemented with ribose ($P = 0.2709$) (Fig. 3b).

201 The infectivity and transmission of *C. difficile* within healthcare settings is facilitated
202 by environmental spore density^{23,24}. To determine the impact of simple sugar availability on
203 spore production rates we assessed the ability of the two lineages to form spores in basal
204 defined medium (BDM) alone or supplemented with either glucose, fructose or ribose. While
205 no difference was observed on the ribose control ($P = 0.3095$), *C. difficile* clade A strains
206 exhibited increased spore production on glucose ($P = 0.0317$) or fructose ($P = 0.0317$) (Fig.
207 3c). These results provide experimental validation and, together with our genomic
208 predictions, suggest that enhanced host colonization and onward spore-mediated transmission
209 with the consumption of simple dietary sugars is a feature of *C. difficile* clade A but not clade
210 B.

211 The rapid recent emergence of *C. difficile* as a significant healthcare pathogen has
212 mainly been attributed to the genomic acquisition of antibiotic resistance and carbohydrate
213 metabolic functions on mobile elements via horizontal gene transfer^{22,25}. Here we show that
214 these recent genomic adaptations have occurred in established, distinct evolutionary lineages

215 each with core genomes expressing unique, pre-existing transmission properties. We reveal
216 the ongoing formation of a new species with biological and phenotypic properties consistent
217 with a transmission cycle that was primed for human transmission in the modern healthcare
218 system (Fig. 3d). Indeed, different transmission dynamics and host epidemiology have also
219 been reported for *C. difficile* clade A (027 lineage²⁶ and 017 lineage²⁷) endemic in healthcare
220 systems in different parts of the world, and the 078 lineage that likely enters the human
221 population from livestock²⁸⁻³⁰. Further, broad epidemiological screens of *C. difficile* present
222 in the healthcare system often highlight high abundances of *C. difficile* clade A as they
223 represent 68.5% (USA), 74% (Europe) and 100% (Mainland China) of the infecting
224 strains^{7,8,31,32}. Thus, we report a link between *C. difficile* clade A speciation, adapted
225 biological pathways and epidemiological patterns. In summary, our study elucidates how
226 bacterial speciation may prime lineages to emerge and transmit in a process accelerated by
227 modern human diet, the acquisition of antibiotic resistance or healthcare regimes.

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245 **Acknowledgements**

246 This work was supported by the Wellcome Trust [098051]; the United Kingdom Medical
247 Research Council [PF451 and MR/K000511/1] and the Australian National Health and
248 Medical Research Council [1091097 to SF] and the Victorian government. The authors thank
249 Scott Weese, Fabio Miyajima, Glen Songer, Thomas Louie, Julian Rood, and Nicholas M.
250 Brown for *C. difficile* strains. The authors thank Anne Neville, Daniel Knight and Bastian
251 Hornung for critical reading and comments. The authors would also like to acknowledge the
252 support of the Wellcome Sanger Institute Pathogen Informatics Team.

253

254 **Author Contributions**

255 N.K. and T.D.L. conceived and managed the study. N.K., S.C.F., E.V., H.P.B. and T.D.L.
256 wrote the manuscript. D.J.F., P.R., M.P., M.R.J.C., M.B.F.J., K.R.H., M.I., L.H.W., C.S.,
257 T.N., G.D., T.V.R., E.J.K., B.W.W. provided critical input and contributed to the editing of
258 the manuscript. N.K. performed the computational analysis. H.P.B. performed genome
259 annotation of reference genomes. D.J.F., P.R., M.P., M.R.J.C., M.B.F.J., K.R.H., M.I.,
260 L.H.W., C.S., T.N. provided *C. difficile* strains. E.V., H.P.B., S.C.F. and T.D.L. designed *in*
261 *vitro* and *in vivo* experiments. H.P.B., E.V. and M.S. performed *in vitro* experiments. E.V.,
262 M.D.S., S.C. and K.H. performed *in vivo* experiments.

263

264 **Conflict of interests**

265 The authors declare no competing financial interests.

266

267

268

269

270 **References:**

- 271 1. Lawrence, J.G. & Retchless, A.C. The interplay of homologous recombination and
272 horizontal gene transfer in bacterial speciation. *Methods Mol Biol* **532**, 29-53 (2009).
- 273 2. Fraser, C., Alm, E.J., Polz, M.F., Spratt, B.G. & Hanage, W.P. The bacterial species
274 challenge: making sense of genetic and ecological diversity. *Science* **323**, 741-6
275 (2009).
- 276 3. Staley, J.T. The bacterial species dilemma and the genomic-phylogenetic species
277 concept. *Philos Trans R Soc Lond B Biol Sci* **361**, 1899-909 (2006).
- 278 4. Moeller, A.H. *et al.* Cospeciation of gut microbiota with hominids. *Science* **353**, 380-
279 382 (2016).
- 280 5. Vandamme, P. *et al.* Polyphasic taxonomy, a consensus approach to bacterial
281 systematics. *Microbiol Rev* **60**, 407-38 (1996).
- 282 6. Cohan, F.M. & Perry, E.B. A systematics for discovering the fundamental units of
283 bacterial diversity. *Curr Biol* **17**, R373-86 (2007).
- 284 7. Martin, J.S., Monaghan, T.M. & Wilcox, M.H. Clostridium difficile infection:
285 epidemiology, diagnosis and understanding transmission. *Nat Rev Gastroenterol*
286 *Hepatol* **13**, 206-16 (2016).
- 287 8. Lessa, F.C., Winston, L.G., McDonald, L.C. & Emerging Infections Program, C.d.S.T.
288 Burden of Clostridium difficile infection in the United States. *N Engl J Med* **372**, 2369-
289 70 (2015).
- 290 9. Stabler, R.A. *et al.* Macro and micro diversity of Clostridium difficile isolates from
291 diverse sources and geographical locations. *PLoS One* **7**, e31559 (2012).
- 292 10. He, M. *et al.* Evolutionary dynamics of Clostridium difficile over short and long time
293 scales. *Proc Natl Acad Sci U S A* **107**, 7527-32 (2010).
- 294 11. Drummond, A.J., Suchard, M.A., Xie, D. & Rambaut, A. Bayesian phylogenetics with
295 BEAUti and the BEAST 1.7. *Mol Biol Evol* **29**, 1969-73 (2012).
- 296 12. Jackson, M. & Spray, E.C. Health and Medicine in the Enlightenment. (Oxford
297 University Press, 2012).
- 298 13. Mostowy, R. *et al.* Efficient Inference of Recent and Ancestral Recombination within
299 Bacterial Populations. *Mol Biol Evol* **34**, 1167-1182 (2017).
- 300 14. Lawley, T.D. *et al.* Proteomic and genomic characterization of highly infectious
301 Clostridium difficile 630 spores. *J Bacteriol* **191**, 5377-86 (2009).
- 302 15. Pettit, L.J. *et al.* Functional genomics reveals that Clostridium difficile Spo0A
303 coordinates sporulation, virulence and metabolism. *BMC Genomics* **15**, 160 (2014).
- 304 16. Fimlaid, K.A. *et al.* Global analysis of the sporulation pathway of Clostridium difficile.
305 *PLoS Genet* **9**, e1003660 (2013).

- 306 17. Lawley, T.D. *et al.* Use of purified *Clostridium difficile* spores to facilitate evaluation
307 of health care disinfection regimens. *Appl Environ Microbiol* **76**, 6895-900 (2010).
- 308 18. Connor, M. *et al.* Evolutionary clade affects resistance of *Clostridium difficile* spores
309 to Cold Atmospheric Plasma. *Sci Rep* **7**, 41814 (2017).
- 310 19. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a
311 reference resource for gene and protein annotation. *Nucleic Acids Res* **44**, D457-62
312 (2016).
- 313 20. Cantarel, B.L. *et al.* The Carbohydrate-Active EnZymes database (CAZy): an expert
314 resource for Glycogenomics. *Nucleic Acids Res* **37**, D233-8 (2009).
- 315 21. Lustig, R.H., Schmidt, L.A. & Brindis, C.D. Public health: The toxic truth about sugar.
316 *Nature* **482**, 27-9 (2012).
- 317 22. Collins, J. *et al.* Dietary trehalose enhances virulence of epidemic *Clostridium*
318 *difficile*. *Nature* (2018).
- 319 23. Browne, H.P. *et al.* Culturing of 'unculturable' human microbiota reveals novel taxa
320 and extensive sporulation. *Nature* **533**, 543-546 (2016).
- 321 24. Merrigan, M. *et al.* Human hypervirulent *Clostridium difficile* strains exhibit
322 increased sporulation as well as robust toxin production. *J Bacteriol* **192**, 4904-11
323 (2010).
- 324 25. Sebahia, M. *et al.* The multidrug-resistant human pathogen *Clostridium difficile* has
325 a highly mobile, mosaic genome. *Nat Genet* **38**, 779-86 (2006).
- 326 26. He, M. *et al.* Emergence and global spread of epidemic healthcare-associated
327 *Clostridium difficile*. *Nat Genet* **45**, 109-13 (2013).
- 328 27. Cairns, M.D. *et al.* Comparative Genome Analysis and Global Phylogeny of the Toxin
329 Variant *Clostridium difficile* PCR Ribotype 017 Reveals the Evolution of Two
330 Independent Sublineages. *J Clin Microbiol* **55**, 865-876 (2017).
- 331 28. Dingle, K.E. *et al.* A Role for Tetracycline Selection in Recent Evolution of Agriculture-
332 Associated *Clostridium difficile* PCR Ribotype 078. *MBio* **10**(2019).
- 333 29. Knetsch, C.W. *et al.* Zoonotic Transfer of *Clostridium difficile* Harboring Antimicrobial
334 Resistance between Farm Animals and Humans. *J Clin Microbiol* **56**(2018).
- 335 30. Knight, D.R., Squire, M.M. & Riley, T.V. Nationwide surveillance study of *Clostridium*
336 *difficile* in Australian neonatal pigs shows high prevalence and heterogeneity of PCR
337 ribotypes. *Appl Environ Microbiol* **81**, 119-23 (2015).
- 338 31. Bauer, M.P. *et al.* *Clostridium difficile* infection in Europe: a hospital-based survey.
339 *Lancet* **377**, 63-73 (2011).
- 340 32. Tang, C. *et al.* The incidence and drug resistance of *Clostridium difficile* infection in
341 Mainland China: a systematic review and meta-analysis. *Sci Rep* **6**, 37865 (2016).
- 342 33. Argimon, S. *et al.* Microreact: visualizing and sharing data for genomic epidemiology
343 and phylogeography. *Microb Genom* **2**, e000093 (2016).
- 344 34. Croucher, N.J. *et al.* Rapid pneumococcal evolution in response to clinical
345 interventions. *Science* **331**, 430-4 (2011).
- 346 35. Harris, S.R. *et al.* Evolution of MRSA during hospital transmission and
347 intercontinental spread. *Science* **327**, 469-74 (2010).
- 348 36. Quail, M.A. *et al.* A large genome center's improvements to the Illumina sequencing
349 system. *Nat Methods* **5**, 1005-10 (2008).
- 350 37. Zerbino, D.R. & Birney, E. Velvet: algorithms for de novo short read assembly using
351 de Bruijn graphs. *Genome Res* **18**, 821-9 (2008).

- 352 38. Boetzer, M., Henkel, C.V., Jansen, H.J., Butler, D. & Pirovano, W. Scaffolding pre-
353 assembled contigs using SSPACE. *Bioinformatics* **27**, 578-9 (2011).
- 354 39. Boetzer, M. & Pirovano, W. Toward almost closed genomes with GapFiller. *Genome*
355 *Biol* **13**, R56 (2012).
- 356 40. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**, 2068-
357 9 (2014).
- 358 41. Chain, P.S. *et al.* Genomics. Genome project standards in a new era of sequencing.
359 *Science* **326**, 236-7 (2009).
- 360 42. Page, A.J. *et al.* Roary: rapid large-scale prokaryote pan genome analysis.
361 *Bioinformatics* **31**, 3691-3 (2015).
- 362 43. Katoh, K. & Standley, D.M. MAFFT multiple sequence alignment software version 7:
363 improvements in performance and usability. *Mol Biol Evol* **30**, 772-80 (2013).
- 364 44. Croucher, N.J. *et al.* Rapid phylogenetic analysis of large samples of recombinant
365 bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* **43**, e15 (2015).
- 366 45. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of
367 large phylogenies. *Bioinformatics* **30**, 1312-3 (2014).
- 368 46. Milne, I. *et al.* TOPALi v2: a rich graphical interface for evolutionary analyses of
369 multiple alignments on HPC clusters and multi-core desktops. *Bioinformatics* **25**, 126-
370 7 (2009).
- 371 47. Ondov, B.D. *et al.* Mash: fast genome and metagenome distance estimation using
372 MinHash. *Genome Biol* **17**, 132 (2016).
- 373 48. Popescu, A.A., Huber, K.T. & Paradis, E. ape 3.0: New tools for distance-based
374 phylogenetics and evolutionary analysis in R. *Bioinformatics* **28**, 1536-7 (2012).
- 375 49. Letunic, I. & Bork, P. Interactive Tree Of Life v2: online annotation and display of
376 phylogenetic trees made easy. *Nucleic Acids Res* **39**, W475-8 (2011).
- 377 50. Delcher, A.L., Phillippy, A., Carlton, J. & Salzberg, S.L. Fast algorithms for large-scale
378 genome alignment and comparison. *Nucleic Acids Res* **30**, 2478-83 (2002).
- 379 51. Cheng, L., Connor, T.R., Siren, J., Aanensen, D.M. & Corander, J. Hierarchical and
380 spatially explicit clustering of DNA sequences with BAPS software. *Mol Biol Evol* **30**,
381 1224-8 (2013).
- 382 52. Tatusov, R.L., Galperin, M.Y., Natale, D.A. & Koonin, E.V. The COG database: a tool
383 for genome-scale analysis of protein functions and evolution. *Nucleic Acids Res* **28**,
384 33-6 (2000).
- 385 53. Jombart, T., Devillard, S. & Balloux, F. Discriminant analysis of principal components:
386 a new method for the analysis of genetically structured populations. *BMC Genet* **11**,
387 94 (2010).
- 388 54. Jombart, T. adegenet: a R package for the multivariate analysis of genetic markers.
389 *Bioinformatics* **24**, 1403-5 (2008).
- 390 55. Yin, Y. *et al.* dbCAN: a web resource for automated carbohydrate-active enzyme
391 annotation. *Nucleic Acids Res* **40**, W445-51 (2012).
- 392 56. Riley, M. Functions of the gene products of Escherichia coli. *Microbiol Rev* **57**, 862-
393 952 (1993).
- 394 57. Kanehisa, M., Sato, Y. & Morishima, K. BlastKOALA and GhostKOALA: KEGG Tools for
395 Functional Characterization of Genome and Metagenome Sequences. *J Mol Biol* **428**,
396 726-731 (2016).
- 397 58. Finn, R.D. *et al.* Pfam: the protein families database. *Nucleic Acids Res* **42**, D222-30
398 (2014).

- 399 59. Lerat, E. & Ochman, H. Recognizing the pseudogenes in bacterial genomes. *Nucleic*
400 *Acids Res* **33**, 3125-32 (2005).
- 401 60. Rambaut, A., Drummond, A.J., Xie, D., Baele, G. & Suchard, M.A. Posterior
402 Summarization in Bayesian Phylogenetics Using Tracer 1.7. *Syst Biol* **67**, 901-904
403 (2018).
- 404 61. Karasawa, T., Ikoma, S., Yamakawa, K. & Nakamura, S. A defined growth medium for
405 *Clostridium difficile*. *Microbiology* **141 (Pt 2)**, 371-5 (1995).
- 406 62. Duncan, S.H., Hold, G.L., Harmsen, H.J., Stewart, C.S. & Flint, H.J. Growth
407 requirements and fermentation products of *Fusobacterium prausnitzii*, and a
408 proposal to reclassify it as *Faecalibacterium prausnitzii* gen. nov., comb. nov. *Int J*
409 *Syst Evol Microbiol* **52**, 2141-6 (2002).

410

411 **Figure legends:**

412 **Figure 1. Phylogeny and population structure of *Clostridium difficile*.** (a) Maximum
413 likelihood tree of 906 *C. difficile* strains constructed from the core genome alignment,
414 excluding recombination events. Collapsed clades as triangles represent four Phylogenetic
415 groups (PG1-4) identified by Bayesian analysis of population structure (BAPS). Number in
416 parentheses indicates number of strains. Key PCR ribotypes in each PG are shown. Bootstrap
417 values of key branches are shown next to the branches. Dates indicate estimated emergence
418 of *C. difficile* species-13.5 million (range 12.7-14.3) years ago, PG4- 385,000 (range
419 297,137-582,886) years ago and PG1-3- 76,000 (range 40,220-214,555) years ago. *C.*
420 *bartlettii*, *C. hiranonis*, *C. ghonii* and *C. sordellii* were used as outgroups to root the tree.
421 Scale bar indicates number of substitutions per site. (b) Distribution pattern of average
422 nucleotide identity (ANI) for 906 *C. difficile* strains. Pairwise ANI calculations between
423 different PGs are shown. Dotted red line indicates bacterial species cut-off.

424

425 **Figure 2. Adaptation of sporulation and metabolic genes in *Clostridium difficile* clade A.**

426 Positive selection analysis of *C. difficile* clade A and B based on 1,322 core genes. (a)
427 Distribution of Ka/Ks ratio for the positively selected genes in *C. difficile* clade A (n = 172
428 genes) and clade B (n = 93 genes) is shown. Error bars are standard error of the mean (SEM).

429 (b) Enriched functions in the positively selected genes of *C. difficile* clade A (n = 172 genes)
430 and clade B (n = 93 genes) are shown. Y-axis represents number of positive selected genes in
431 each enriched function. All are statistically significant (sugar phosphotransferase system (q =
432 0.00167), fructose and mannose metabolism (q = 0.001173), sporulation, differentiation and
433 germination (q = 0.0165), cysteine and methionine metabolism (q = 0.00279), sulphur relay
434 system (q = 0.00791)). One-sided Fisher's exact test with *P* value adjusted by Hochberg
435 method. (c) Positively selected sporulation-associated genes in *C. difficile* clade A are shown
436 in blue. Of the 172 genes under positive selection, 26% (45 in total) are either involved in
437 spore production (sporulation stages I, III, IV and V), their proteins are present in the mature
438 spore proteome or they are regulated by Spo0A or its sporulation specific sigma factors.

439

440 **Figure 3. Bacterial speciation is linked to increased host adaptation and transmission**

441 **ability.** (a) Spores of *C. difficile* clade A are more resistant to widely used hydrogen peroxide
442 disinfectant. Spores of *C. difficile* clade A and clade B (n = 5 different ribotypes for both
443 lineages) were exposed to hydrogen peroxide for 5 minutes, washed and plated. Recovered
444 CFUs representing surviving germinated spores were counted and presented as a percentage
445 of spores exposed to PBS. Mean and range of 3 independent experiments is presented, Mann-
446 Whitney unpaired two-tailed test. (b) Intestinal colonization of clade A strains is increased in
447 the presence of simple sugars compared to clade B strains. Comparison of vegetative cell
448 loads between *C. difficile* clade A (n = 1, RT027) and clade B (n = 1, RT078) strains in mice
449 whose diet was supplemented with different sugars before challenging with spores. CFUs
450 from fecal samples cultured 16 hours after *C. difficile* challenge are presented. Mean values
451 of 5 mice are presented from 1 representative experiment which was repeated once with
452 similar results, standard error of the mean (SEM), unpaired two-tailed *t* test. (c) Clade A
453 strains produce more spores in the presence of simple sugars. *C. difficile* clade A and clade B

454 (n = 5 different ribotypes for both lineages) strains were grown on basal defined media in the
455 presence or absence of different sugars, vegetative cells were killed by ethanol exposure and
456 the number of CFUs representing germinated spores were counted. The percentage of spores
457 recovered in the presence of sugars compared to BDM alone is presented. Mean and range of
458 3 independent experiments is presented, Mann-Whitney unpaired two-tailed test. (d)
459 Overview of adaptations in key aspects of the *C. difficile* clade A transmission cycle in
460 human population.

461

462 **Online Methods**

463 **Collection of *C. difficile* strains**

464 Laboratories worldwide were asked to send a diverse representation of their *C.*
465 *difficile* collections to the Wellcome Sanger Institute (WSI). After receiving all shipped
466 samples the DNA extraction was performed batch-wise using the same protocol and reagents
467 to minimize bias. Phenol-Chloroform was the preferred method for extraction since it
468 provides high DNA yield and intact chromosomal DNA.

469 The genomes of 382 strains designated as *C. difficile*, by PCR ribotyping were sequenced and
470 combined with our previous collection of 506 *C. difficile* strains, 13 high quality *C. difficile*
471 reference strains and 5 publicly available *C. difficile* RT 244 strains making a total of 906
472 strains analyzed in this study. This genome collection includes strains from humans (n =
473 761), animals (n =116) and the environment (n = 29) that were collected from diverse
474 geographic locations (UK; n = 465, Europe; n = 230, N-America; n = 111, Australia; n = 62,
475 Asia; n = 38). Details of all strains are listed in Supplementary Table 1 and Supplementary
476 Table 2, including the European Nucleotide Archive (ENA) sample accession numbers.
477 Metadata of this *C. difficile* collection have been made freely publicly available through
478 Microreact³³ (<https://microreact.org/project/H1QidSp14>).

479 **Bacterial culture and genomic DNA preparation**

480 *C. difficile* strains were cultured on blood agar plates for 48 hours, inoculated into
481 brain–heart infusion broth supplemented with yeast extract and cysteine and grown overnight
482 (16 hours) anaerobically at 37 °C. Cells were pelleted, washed with PBS, and genomic DNA
483 preparation was performed using a phenol–chloroform extraction as previously described³⁴.
484 All culturing of *C. difficile* took place in anaerobic conditions (10% CO₂, 10% H₂, 80% N₂)
485 in a Whitley DG250 workstation at 37 °C. All reagents and media were reduced for 24
486 hours in anaerobic conditions before use.

487 **DNA sequencing, assembly and annotation**

488 Paired-end multiplex libraries were prepared and sequenced using Illumina Hi-Seq
489 platform with fragment size of 200-300 bp and a read length of 100 bp, as previously
490 described^{35,36}. An in-house pipeline developed at the WSI ([https://github.com/sanger-
491 pathogens/Bio-AutomatedAnnotation](https://github.com/sanger-pathogens/Bio-AutomatedAnnotation)) was used for bacterial assembly and annotation. It
492 consisted of *de novo* assembly for each sequenced genome using Velvet v1.2.10³⁷, SSPACE
493 v2.0³⁸ and GapFiller v1.1³⁹ followed by annotation using Prokka v1.5-1⁴⁰. For the 13 high-
494 quality reference genomes, strains Liv024, TL178, TL176, TL174, CD305 and Liv022 were
495 sequenced using 454 and Illumina sequencing platforms, BI-9 and M68 were sequenced
496 using 454 and capillary sequencing technologies with the assembled data for these 8 strains
497 been improved to an ‘Improved High Quality Draft’ genome standard⁴¹. Optical maps using
498 the Argus Optical Mapping system were also generated for Liv024, TL178, TL176, TL174,
499 CD305 and Liv022. The remaining strains are all contiguous and were all sequenced using
500 454 and capillary sequencing technologies except for R20291 which also had Illumina data
501 incorporated and 630 which was sequenced using capillary sequence data alone.

502 **Phylogenetic analysis, Pairwise SNP distances analysis and Average Nucleotide Identity**
503 **analysis**

504 The phylogenetic analysis was conducted by extracting nucleotide sequence of 1,322
505 single copy core gene from each *C. difficile* genome using Roary⁴². The nucleotide sequences
506 were concatenated and aligned with MAFFT v7.20⁴³. Gubbins⁴⁴ was used to mask
507 recombination from concatenated alignment of these core genes and a maximum-likelihood
508 tree was constructed using RAxML v8.2.8⁴⁵ with the best-fit model of nucleotide substitution
509 (GTRGAMMA) calculated from ModelTest embedded in TOPALi v2.5⁴⁶ and 500 bootstrap
510 replicates. The phylogeny was rooted using a distance-based tree generated using Mash
511 v2.0⁴⁷, R package APE⁴⁸ and genome assemblies of closely related species (*C. bartlettii*, *C.*
512 *hiranonis*, *C. ghonii* and *C. sordellii*). All phylogenetic trees were visualized in iTOL⁴⁹.
513 Genomes of closely related *C. difficile* were downloaded from NCBI. Pairwise SNP distances
514 analysis was performed on concatenated alignment of 1,322 single-copy core genes using
515 SNP-Dist (<https://github.com/tseemann/snp-dists>). Average nucleotide analysis (ANI) was
516 calculated by performing pairwise comparison of genome assemblies using MUMmer⁵⁰.

517 **Population structure and recombination analysis**

518 Population structure based on concatenated alignment of 1,322 single-copy core genes
519 of *C. difficile* was inferred using the HierBAPS⁵¹ with one clustering layers and 5, 10 and 20
520 expected numbers of clusters (k) as input parameters. Recombination events across the
521 whole-genome sequences were detected by mapping genomes against a reference genome
522 (NCTC 13366; RT027) and using FastGear¹³ with default parameters.

523 **Functional genomic analysis**

524 To explore accessory genome and identify protein domains in a genome, we
525 performed RPS-BLAST using COG database (accessed February 2019)⁵². All protein
526 domains were classified in different functional categories using the COG database⁵² and were
527 used to perform Discriminant Analysis of Principle Components (DAPC)⁵³ implemented in

528 the R package Adegnet v2.0.1⁵⁴. Domain and functional enrichment analysis was calculated
529 using one-sided Fisher's exact test with *P* value adjusted by Hochberg method in R v3.2.2.

530 Carbohydrate active enzymes (CAZymes) in a genome were identified using dbCAN
531 v5.0⁵⁵ (HMM database of carbohydrate active enzyme annotation). Best hits include hits with
532 E-value $< 1 \times 10^{-5}$ if alignment > 80 aa and hits with E-value $< 1 \times 10^{-3}$ if alignment < 80 aa,
533 and alignment coverage > 0.3 . Best hits were used to perform Discriminant Analysis of
534 Principle Components (DAPC)⁵³ implemented in the R package Adegnet v2.0.1⁵⁴.

535 Functional annotation of positively selected genes was carried out using the Riley
536 classification system⁵⁶, KEGG Orthology⁵⁷ and Pfam functional families⁵⁸.

537 **Analysis of selective pressures.**

538 The aligned nucleotide sequences of each 1,322 single copy core genes were extracted
539 from Roary's output. The ratio between the number of non-synonymous mutations (Ka) and
540 the number of synonymous mutations (Ks) was calculated for the whole alignment and for
541 the respective subsets of strains belonging to the PG1, 2, 3 as a group and PG4. The Ka/Ks
542 ratio for each gene alignment was calculated with SeqinR v3.1. A Ka/Ks > 1 was considered
543 as the threshold for identifying genes under positive selection.

544 **Pseudogenes analysis**

545 Nucleotide annotations of genes within a genome within each phylogenetic group
546 were mapped against the protein sequences of the reference genome for its phylogenetic
547 group (PG1: NCTC 13307(RT012), PG2: SRR2751302 (RT244), PG3: NCTC 14169
548 (RT017), PG4: NCTC 14173 (RT078)) using TBLASTN as previously described⁵⁹.
549 Pseudogenes were called based on following criteria: genes with E value $> 1 \times 10^{-30}$ and
550 sequence identity $< 99\%$ and which are absent in 90% members of a phylogenetics group.
551 Genes in the reference genomes annotated as a pseudogene were also included in addition to
552 genes in query genomes.

553 **Analysis of estimating dates**

554 The aligned nucleotide sequences of each 222 core genes of *C. difficile* which are
555 under neutral selection ($Ka/Ks = 1$) were extracted from Roary's output. Gubbins⁴⁴ was used
556 to mask recombination from concatenated alignment of these core genes and used as an input
557 for Bayesian Evolutionary Analysis Sampling Trees (BEAST) software package v2.4.1¹¹. In
558 BEAST, the MCMC chain was run for 50 million generations, sampling every 1,000 states
559 using the strict clock model ($2.50 \times 10^{-9} - 1.50 \times 10^{-8}$ per site per year)¹⁰ and HKY four
560 discrete gamma substitution model, each run in triplicate. Convergence of parameters were
561 verified with Tracer v1.5⁶⁰ by inspecting the Effective Sample Sizes ($ESS > 200$).
562 LogCombiner was used to remove 10% of the MCMC steps discarded as burn-ins and
563 combine triplicates. The resulting file was used to infer the time of divergence from the most
564 recent common ancestor for *C. difficile*, *C. difficile* clade A and clade B. The Bayesian
565 skyline plot was generated with Tracer v1.5⁶⁰.

566 ***C. difficile* growth in vitro on selected carbon sources**

567 Basal defined medium (BDM)⁶¹ was used as the minimal medium to which selected
568 carbon sources (2 g/l of glucose, fructose or ribose from Sigma-Aldrich) were added. *C.*
569 *difficile* strains were grown on CCEY agar (Bioconnections) for two days; 125-ml
570 Erlenmeyer flasks containing 10 ml of BDM with or without carbon sources were inoculated
571 with *C. difficile* strains and incubated in anaerobic conditions at 37 °C shaking at 180 rpm.
572 After 48 hours, spores were enumerated by centrifuging the culture to a pellet, carefully
573 decanting the BDM and re-suspending in 70% ethanol for 4 hours to kill vegetative cells.
574 Following ethanol shock, spores were washed twice in PBS and plated in a serial dilution on
575 YCFA media⁶² supplemented with 0.1% sodium taurocholate. Colony forming units
576 (representing germinated spores) were counted 24 hours later. The experiment was performed
577 independently 3 times for each strain. Clade A strains used were TL178 (RT002/ PG1),

578 TL174 (RT015/ PG1), R20291 (RT027/ PG2), CF5 (RT017/ PG3) and CD305 (RT023/
579 PG3). Clade B strains used were MON024 (RT033), CDM120 (RT078), WA12 (RT291),
580 WA13 (RT228) and MON013 (RT127). Data were presented using GraphPad Prism v7.03.

581 ***C. difficile* spore resistance to disinfectant**

582 Spores were prepared by adapting the previous protocol¹⁸. In brief, *C. difficile* strains
583 were streaked on CCEY media, the cells were harvested from the plates 48 hours later and
584 subjected to exposure in 70% ethanol for 4 hours to kill vegetative cells. The solution was
585 then centrifuged, ethanol was decanted and the spores were washed once in 5 ml sterile saline
586 (0.9% w/v) solution before being suspended in 5 ml of saline (0.9% w/v) with Tween20
587 (0.05% v/v). 300 µl spore suspensions (at a concentration of approximately 10⁶ spores) were
588 exposed to 300 µl of 3%, 10% and 30% hydrogen peroxide (Fisher Scientific UK Limited)
589 solutions for 5 minutes in addition to 300 µl PBS. The suspensions were then centrifuged,
590 hydrogen peroxide or PBS was decanted and the spores were washed twice with PBS.
591 Washed spores were plated on YCFA media with 0.1% sodium taurocholate to stimulate
592 spore germination and colony forming units were counted 24 hours later. The experiment was
593 performed independently 3 times for each strain. Clade A strains used were TL178 (RT002/
594 PG1), TL174 (RT015/ PG1), R20291 (RT027/ PG2), CF5 (RT017/ PG3) and CD305
595 (RT023/ PG3). Clade B strains used were MON024 (RT033), CDM120 (RT078), WA12
596 (RT291), WA13 (RT228) and MON013 (RT127). Data were presented using GraphPad
597 Prism v7.03.

598 ***In vivo C. difficile* colonization experiment**

599 Five female 8-week-old C57BL/6 mice were given 250 mg/l clindamycin (Apollo
600 Scientific) in drinking water. After 5 days, clindamycin treatment was interrupted and 100
601 mM of glucose, fructose or ribose was added to mouse drinking water for the rest of the
602 experiment; no sugars were given to control mice. After 3 days, mice were infected orally

603 with 6×10^3 spore/mouse of *C. difficile* R20291 (RT027) or M120 (RT078) strain. Fecal
604 samples were collected from all mice before infection to check for pre-existing *C. difficile*
605 contamination. Spore suspensions were prepared as described above¹⁸. After 16 hours, fecal
606 samples were collected from all mice to determine viable *C. difficile* cell counts by serial
607 dilution and plating on CCEY agar supplemented with 0.1% sodium taurocholate. The mean
608 values of 5 mice are presented from 1 representative experiment which was repeated once
609 with similar results. Data were presented using GraphPad Prism version 7.03. Ethical
610 approval for mouse experiments was obtained from the Wellcome Sanger Institute.

611 **Reporting Summary**

612 Further information on research design is available in the Life Sciences Reporting
613 Summary linked to this article.

614 **Data Availability**

615 Genomes have been deposited in the European Nucleotide Archive. Accession codes
616 are listed in Supplementary Table 1. The 13 *C. difficile* reference isolates (Supplementary
617 Table 2) are publicly available from the National Collection of Type Cultures (NCTC) and
618 the annotation of these genomes are available from the Host-Microbiota Interactions Lab
619 (HMIL; www.lawleylab.com), Wellcome Sanger Institute.

620 **Code Availability**

621 No custom code was used.

622

623

624

625

626

627

628
629
630
631
632
633
634
635
636
637

638 **Methods-only References**

- 639
640 33. Argimon, S. *et al.* Microreact: visualizing and sharing data for genomic epidemiology
641 and phylogeography. *Microb Genom* **2**, e000093 (2016).
642 34. Croucher, N.J. *et al.* Rapid pneumococcal evolution in response to clinical
643 interventions. *Science* **331**, 430-4 (2011).
644 35. Harris, S.R. *et al.* Evolution of MRSA during hospital transmission and
645 intercontinental spread. *Science* **327**, 469-74 (2010).
646 36. Quail, M.A. *et al.* A large genome center's improvements to the Illumina sequencing
647 system. *Nat Methods* **5**, 1005-10 (2008).
648 37. Zerbino, D.R. & Birney, E. Velvet: algorithms for de novo short read assembly using
649 de Bruijn graphs. *Genome Res* **18**, 821-9 (2008).
650 38. Boetzer, M., Henkel, C.V., Jansen, H.J., Butler, D. & Pirovano, W. Scaffolding pre-
651 assembled contigs using SSPACE. *Bioinformatics* **27**, 578-9 (2011).
652 39. Boetzer, M. & Pirovano, W. Toward almost closed genomes with GapFiller. *Genome*
653 *Biol* **13**, R56 (2012).
654 40. Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**, 2068-9
655 (2014).
656 41. Chain, P.S. *et al.* Genomics. Genome project standards in a new era of sequencing.
657 *Science* **326**, 236-7 (2009).
658 42. Page, A.J. *et al.* Roary: rapid large-scale prokaryote pan genome analysis.
659 *Bioinformatics* **31**, 3691-3 (2015).
660 43. Katoh, K. & Standley, D.M. MAFFT multiple sequence alignment software version 7:
661 improvements in performance and usability. *Mol Biol Evol* **30**, 772-80 (2013).
662 44. Croucher, N.J. *et al.* Rapid phylogenetic analysis of large samples of recombinant
663 bacterial whole genome sequences using Gubbins. *Nucleic Acids Res* **43**, e15 (2015).
664 45. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis
665 of large phylogenies. *Bioinformatics* **30**, 1312-3 (2014).

- 666 46. Milne, I. *et al.* TOPALi v2: a rich graphical interface for evolutionary analyses of
667 multiple alignments on HPC clusters and multi-core desktops. *Bioinformatics* **25**, 126-
668 7 (2009).
- 669 47. Ondov, B.D. *et al.* Mash: fast genome and metagenome distance estimation using
670 MinHash. *Genome Biol* **17**, 132 (2016).
- 671 48. Popescu, A.A., Huber, K.T. & Paradis, E. ape 3.0: New tools for distance-based
672 phylogenetics and evolutionary analysis in R. *Bioinformatics* **28**, 1536-7 (2012).
- 673 49. Letunic, I. & Bork, P. Interactive Tree Of Life v2: online annotation and display of
674 phylogenetic trees made easy. *Nucleic Acids Res* **39**, W475-8 (2011).
- 675 50. Delcher, A.L., Phillippy, A., Carlton, J. & Salzberg, S.L. Fast algorithms for large-
676 scale genome alignment and comparison. *Nucleic Acids Res* **30**, 2478-83 (2002).
- 677 51. Cheng, L., Connor, T.R., Siren, J., Aanensen, D.M. & Corander, J. Hierarchical and
678 spatially explicit clustering of DNA sequences with BAPS software. *Mol Biol Evol*
679 **30**, 1224-8 (2013).
- 680 52. Tatusov, R.L., Galperin, M.Y., Natale, D.A. & Koonin, E.V. The COG database: a
681 tool for genome-scale analysis of protein functions and evolution. *Nucleic Acids Res*
682 **28**, 33-6 (2000).
- 683 53. Jombart, T., Devillard, S. & Balloux, F. Discriminant analysis of principal
684 components: a new method for the analysis of genetically structured populations.
685 *BMC Genet* **11**, 94 (2010).
- 686 54. Jombart, T. adegenet: a R package for the multivariate analysis of genetic markers.
687 *Bioinformatics* **24**, 1403-5 (2008).
- 688 55. Yin, Y. *et al.* dbCAN: a web resource for automated carbohydrate-active enzyme
689 annotation. *Nucleic Acids Res* **40**, W445-51 (2012).
- 690 56. Riley, M. Functions of the gene products of Escherichia coli. *Microbiol Rev* **57**, 862-
691 952 (1993).
- 692 57. Kanehisa, M., Sato, Y. & Morishima, K. BlastKOALA and GhostKOALA: KEGG
693 Tools for Functional Characterization of Genome and Metagenome Sequences. *J Mol*
694 *Biol* **428**, 726-731 (2016).
- 695 58. Finn, R.D. *et al.* Pfam: the protein families database. *Nucleic Acids Res* **42**, D222-30
696 (2014).
- 697 59. Lerat, E. & Ochman, H. Recognizing the pseudogenes in bacterial genomes. *Nucleic*
698 *Acids Res* **33**, 3125-32 (2005).
- 699 60. Rambaut, A., Drummond, A.J., Xie, D., Baele, G. & Suchard, M.A. Posterior
700 Summarization in Bayesian Phylogenetics Using Tracer 1.7. *Syst Biol* **67**, 901-904
701 (2018).
- 702 61. Karasawa, T., Ikoma, S., Yamakawa, K. & Nakamura, S. A defined growth medium
703 for Clostridium difficile. *Microbiology* **141** (Pt 2), 371-5 (1995).
- 704 62. Duncan, S.H., Hold, G.L., Harmsen, H.J., Stewart, C.S. & Flint, H.J. Growth
705 requirements and fermentation products of Fusobacterium prausnitzii, and a proposal
706 to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. *Int J Syst Evol*
707 *Microbiol* **52**, 2141-6 (2002).

709
710
711
712
713
714

715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730

731

732

733